Data from Tisotumab Vedotin in Previously Treated Recurrent or Metastatic Cervical Cancer

Autor: Robert L. Coleman, Ulrik Niels Lassen, Jeffrey R. Harris, Kristian Windfeld, Srinivas Ghatta, Reshma A. Rangwala, Fiona C. Thistlethwaite, Melissa L. Johnson, Christine Gennigens, Nathalie Cornez, Martin D. Forster, Robert Jones, James F. Spicer, Jean-Pascal Machiels, Hendrik-Tobias Arkenau, Yvette Drew, Brian M. Slomovitz, Johann S. de Bono, Ignace Vergote, Nicole Concin, David S. Hong

Purpose:Tissue factor (TF) is a potential target in cervical cancer, as it is frequently highly expressed and associated with poor prognosis. Tisotumab vedotin, a first-in-class investigational antibody–drug conjugate targeting TF, has demonstrated

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f38b252c0896291d3186928e260eb23
https://doi.org/10.1158/1078-0432.c.6529863.v1

A phase 1b/2 study of batiraxcept (AVB-S6-500) in combination with cabozantinib, cabozantinib and nivolumab, and as monotherapy in patients with advanced or metastatic clear cell renal cell carcinoma (NCT04300140)

Autor: Katy Beckermann, Neil J. Shah, Nicholas J. Vogelzang, Shifeng S. Mao, Moshe Chaim Ornstein, Hans J. Hammers, Xin Gao, David F. McDermott, Naomi B. Haas, Hongxia Yan, Vanessa Esquibel, Reshma A. Rangwala, Matthew T Campbell

Publikováno v: Journal of Clinical Oncology. 40:TPS4599-TPS4599

TPS4599 Background: In clear cell renal cell carcinoma (ccRCC) the constitutive expression of hypoxia induced factor 1-α leads to increased expression of AXL. AXL overexpression has been associated with the development of resistance to VEGF inhibito

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d29085ea13bca38cb074b77c9963e2ba
https://doi.org/10.1200/jco.2022.40.16_suppl.tps4599

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6):a multicentre, open-label, single-arm, phase 2 study

Autor: Ugo De Giorgi, Bohuslav Melichar, Bente Lund, Signe Diness Vindeløv, Antonio González-Martín, Jeffrey R. Harris, Francesco Raspagliesi, Michael Gold, Claudio Zamagni, Andrés Redondo, Nicole Concin, Brigitte Honhon, Maria Bjurberg, Sandro Pignata, Melinda S L Teng, Matthew Schlumbrecht, Meaghan Tenney, Mansoor Raza Mirza, Reshma A. Rangwala, Charles Leath, Robert L. Coleman, Domenica Lorusso, Annouschka Laenen, Eveline De Cuypere, Lydia Gaba Garcia, Giovanni Scambia, Sven Mahner, William H. Bradley, Carolyn Muller, Nicola Spirtos, Margaret Smith, David Cibula, Leslie M Randall, Bradley J. Monk, Philipp Harter, Stephanie Henry, Sumeet Bhatia, Joshua Cohen, Menghui Chen, Christine Gennigens, Ignace Vergote, Luis Manso, Zdenek Kral, Amanda Jackson, Robin Farias-Eisner, Jean-Francois Baurain, Christof Vulsteke, David M. O'Malley, Frederic Forget, Linn Woelber, Mary Gordinier, Hannelore Denys, Leonardo Viana Nicacio

Publikováno v: Coleman, R L, Lorusso, D, Gennigens, C, González-Martín, A, Randall, L, Cibula, D, Lund, B, Woelber, L, Pignata, S, Forget, F, Redondo, A, Vindeløv, S D, Chen, M, Harris, J R, Smith, M, Nicacio, L V, Teng, M S L, Laenen, A, Rangwala, R, Manso, L, Mirza, M, Monk, B J, Vergote, I & The innovaTV 204/GOG-3023/ENGOT-cx6 Collaborators 2021, ' Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6) : a multicentre, open-label, single-arm, phase 2 study ', The Lancet Oncology, vol. 22, no. 5, pp. 609-619 . https://doi.org/10.1016/S1470-2045(21)00056-5

Summary Background Few effective second-line treatments exist for women with recurrent or metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of tisotumab vedotin, a tissue factor-directed antibody–drug conjugate,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::602debc1a5b7e94c93fe44ed1aa57b6a
https://vbn.aau.dk/da/publications/b1ba31e5-0840-4941-91b2-2218550c4b91

Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial

Autor: Martin Reck, Rina Hui, Maya Gottfried, Gregory M. Lubiniecki, Sinead Cuffe, Suman Rao, Katsuyuki Hotta, Tibor Csőszi, Anne C. Deitz, Delvys Rodriguez-Abreu, Julie R. Brahmer, Nir Peled, Mary O'Brien, Andrew G. Robinson, Ali Tafreshi, Andrea Fülöp, Jin Zhang, Reshma A. Rangwala

Publikováno v: The Lancet Oncology. 18:1600-1609

Summary Background In the phase 3 KEYNOTE-024 trial, treatment with pembrolizumab conferred longer progression-free survival than did platinum-based therapy in patients with treatment-naive, advanced non-small-cell lung cancer (NSCLC) with a programm

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1d4d339d84d10f47a17bacb5b670a2b6
https://doi.org/10.1016/s1470-2045(17)30690-3

Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial

Autor: Charlotte Roach, Myung-Ju Ahn, Amita Patnaik, Matthew D. Hellmann, Naiyer A. Rizvi, Enriqueta Felip, Rina Hui, Jin Zhang, Leena Gandhi, Edward B. Garon, Jonathan W. Goldman, Leora Horn, Gregory M. Lubiniecki, Joseph Paul Eder, Reshma A. Rangwala, Natasha B. Leighl, Enric Carcereny, Kenneth Emancipator

Publikováno v: Annals of Oncology. 28:874-881

Background Pembrolizumab improved survival as first- and second-line therapy compared with chemotherapy in patients with highly programmed death ligand 1 (PD-L1) expressing advanced non-small cell lung cancer (NSCLC). We report the long-term safety a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b8cd86d98d40cb813c22e10c512ea1d
https://doi.org/10.1093/annonc/mdx008